MX2009009133A - Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona. - Google Patents
Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.Info
- Publication number
- MX2009009133A MX2009009133A MX2009009133A MX2009009133A MX2009009133A MX 2009009133 A MX2009009133 A MX 2009009133A MX 2009009133 A MX2009009133 A MX 2009009133A MX 2009009133 A MX2009009133 A MX 2009009133A MX 2009009133 A MX2009009133 A MX 2009009133A
- Authority
- MX
- Mexico
- Prior art keywords
- naloxone
- buprenorphine
- medicinal compositions
- improved medicinal
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- SFNLWIKOKQVFPB-KZCPYJDTSA-N bunavail Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C.C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 SFNLWIKOKQVFPB-KZCPYJDTSA-N 0.000 title abstract 2
- 230000036592 analgesia Effects 0.000 abstract 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 1
- 229960001736 buprenorphine Drugs 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 abstract 1
- 229960004127 naloxone Drugs 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona una composición para el tratamiento de dolor en pacientes humanos en donde dicha composición comprende buprenorfina a naloxona en una relación en peso de 2.1:1 a 8:1, la cantidad de buprenorfina y naloxona es adecuada para proporcionar analgesia, la composición está en una forma de dosificación transdérmica o transmucósica. También se proporciona un método y uso relacionado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0703967A GB2447015A (en) | 2007-03-01 | 2007-03-01 | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| PCT/GB2008/000523 WO2008104737A1 (en) | 2007-03-01 | 2008-02-15 | Improved medicinal compositions comprising buprenorphine and naloxone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009009133A true MX2009009133A (es) | 2009-09-03 |
Family
ID=37965734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009009133A MX2009009133A (es) | 2007-03-01 | 2008-02-15 | Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100168147A1 (es) |
| EP (1) | EP2114453A1 (es) |
| JP (1) | JP2010520185A (es) |
| KR (1) | KR20090115863A (es) |
| CN (2) | CN101622013A (es) |
| AR (1) | AR065581A1 (es) |
| AU (1) | AU2008220573A1 (es) |
| BR (1) | BRPI0807905A2 (es) |
| CA (1) | CA2678675A1 (es) |
| CL (1) | CL2008000610A1 (es) |
| GB (1) | GB2447015A (es) |
| MX (1) | MX2009009133A (es) |
| PE (1) | PE20081874A1 (es) |
| TW (1) | TW200836738A (es) |
| WO (1) | WO2008104737A1 (es) |
| ZA (1) | ZA200905691B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2658585C (en) | 2006-07-21 | 2011-03-01 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
| CN102056578A (zh) * | 2008-06-23 | 2011-05-11 | 生物递送科学国际公司 | 多向粘膜给药装置及使用方法 |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| MX352959B (es) | 2011-08-18 | 2017-12-15 | Biodelivery Sciences Int Inc | Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina. |
| RS62505B1 (sr) | 2011-09-19 | 2021-11-30 | Orexo Ab | Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson |
| US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| US20140275148A1 (en) * | 2013-03-15 | 2014-09-18 | Novus Pharma LLC | Orally administrable, self-supporting dissolving film dosage forms |
| WO2015095644A1 (en) | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| WO2015136373A1 (en) | 2014-03-14 | 2015-09-17 | Lightlake Therapeutics Inc. | Nasal drug products and methods of their use |
| US20250144015A1 (en) | 2023-11-06 | 2025-05-08 | Extrovis Ag | Pharmaceutical Compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| JP2001526229A (ja) * | 1997-12-22 | 2001-12-18 | ユーロ−セルティーク，エス．エイ． | オピオイド投薬剤形の乱用を防止する方法 |
| AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| US20050191340A1 (en) * | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
| ATE367155T1 (de) * | 2002-08-09 | 2007-08-15 | Gruenenthal Gmbh | Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin |
| EP1584335A3 (en) * | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising a carbinol composition and an opioid |
| US8236751B2 (en) * | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
-
2007
- 2007-03-01 GB GB0703967A patent/GB2447015A/en not_active Withdrawn
-
2008
- 2008-02-15 CA CA002678675A patent/CA2678675A1/en not_active Abandoned
- 2008-02-15 MX MX2009009133A patent/MX2009009133A/es unknown
- 2008-02-15 EP EP08709414A patent/EP2114453A1/en not_active Withdrawn
- 2008-02-15 JP JP2009551255A patent/JP2010520185A/ja not_active Ceased
- 2008-02-15 US US12/529,309 patent/US20100168147A1/en not_active Abandoned
- 2008-02-15 KR KR1020097018324A patent/KR20090115863A/ko not_active Ceased
- 2008-02-15 CN CN200880006847A patent/CN101622013A/zh active Pending
- 2008-02-15 CN CN2012101207560A patent/CN102670610A/zh active Pending
- 2008-02-15 WO PCT/GB2008/000523 patent/WO2008104737A1/en active Application Filing
- 2008-02-15 AU AU2008220573A patent/AU2008220573A1/en not_active Abandoned
- 2008-02-15 BR BRPI0807905-6A2A patent/BRPI0807905A2/pt not_active IP Right Cessation
- 2008-02-27 TW TW097106772A patent/TW200836738A/zh unknown
- 2008-02-28 CL CL200800610A patent/CL2008000610A1/es unknown
- 2008-02-29 AR ARP080100882A patent/AR065581A1/es not_active Application Discontinuation
- 2008-02-29 PE PE2008000412A patent/PE20081874A1/es not_active Application Discontinuation
-
2009
- 2009-08-17 ZA ZA200905691A patent/ZA200905691B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008220573A1 (en) | 2008-09-04 |
| ZA200905691B (en) | 2010-10-27 |
| TW200836738A (en) | 2008-09-16 |
| CL2008000610A1 (es) | 2008-09-05 |
| CN102670610A (zh) | 2012-09-19 |
| BRPI0807905A2 (pt) | 2014-06-17 |
| CN101622013A (zh) | 2010-01-06 |
| JP2010520185A (ja) | 2010-06-10 |
| WO2008104737A1 (en) | 2008-09-04 |
| KR20090115863A (ko) | 2009-11-09 |
| US20100168147A1 (en) | 2010-07-01 |
| GB2447015A (en) | 2008-09-03 |
| GB0703967D0 (en) | 2007-04-11 |
| PE20081874A1 (es) | 2009-01-26 |
| CA2678675A1 (en) | 2008-09-04 |
| AR065581A1 (es) | 2009-06-17 |
| EP2114453A1 (en) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009009133A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona. | |
| MX2009009132A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. | |
| MX2009009131A (es) | Mejoras en y con relacion a composiciones medicinales. | |
| MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
| IL244974B (en) | Preparations in flat form containing buprenorphine and naloxone, formulations in flat form containing them, and their use in the preparation of drugs for the treatment of narcotic dependence | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| NZ597378A (en) | Treatment of multiple sclerosis with laquinimod | |
| JP2010520186A5 (es) | ||
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| NZ589733A (en) | Oral administration of peripherally-acting opioid antagonists | |
| JP2010520183A5 (es) | ||
| WO2007018588A8 (en) | Stable pharmaceutical composition comprising linezolid form iv | |
| JP2010520185A5 (es) | ||
| MX2009009134A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno. | |
| DE502005005636D1 (en) | Spirocyclische cyclohexan-derivate | |
| WO2005081742A3 (en) | Testosterone oral dosage formulations and associated methods | |
| TNSN08506A1 (en) | Substituted carboxamides | |
| PT1730147E (pt) | Compostos de 1,4,8-triazaspiro[4.5]decan-2-ona substituídos para utilização no tratamento da obesidade | |
| NZ719087A (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
| MX347237B (es) | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. | |
| MX2007004955A (es) | Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente. | |
| MX2009013197A (es) | Derivados terapeuticos de pirazolonaftiridina. | |
| MX367580B (es) | El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer. | |
| MX2008015323A (es) | Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |